A5086007942- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Cancer, Lipids, and Metabolism
- Health Systems, Economic Evaluations, Quality of Life
- Global Cancer Incidence and Screening
- Statistical Methods in Clinical Trials
- Urologic and reproductive health conditions
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Colorectal Cancer Screening and Detection
- Radiomics and Machine Learning in Medical Imaging
- Economic and Financial Impacts of Cancer
- Urological Disorders and Treatments
- Genital Health and Disease
- Immunotherapy and Immune Responses
- Healthcare Policy and Management
- Lipoproteins and Cardiovascular Health
- Advanced Radiotherapy Techniques
- Urinary Bladder and Prostate Research
- Pelvic floor disorders treatments
- Molecular Biology Techniques and Applications
- Cancer survivorship and care
- Cancer Genomics and Diagnostics
- Hormonal and reproductive studies
University of California, San Francisco
2016-2025
University of California San Francisco Medical Center
2015-2025
UCSF Helen Diller Family Comprehensive Cancer Center
2015-2024
San Francisco VA Medical Center
2015-2024
Memorial Sloan Kettering Cancer Center
2004-2023
Urological Society of Australia and New Zealand
2023
Princess Margaret Cancer Centre
2016-2023
Astellas Pharma (United Kingdom)
2023
Dendreon (United States)
2019-2023
John Wiley & Sons (United States)
2016-2023
PURPOSE In the absence of high-level evidence or clinical guidelines supporting any given active treatment approach over another for localized prostate cancer, clinician and patient preferences may lead to substantial variation in use. METHODS Data were analyzed from 36 sites that contributed data Cancer Prostate Strategic Urologic Research Endeavor (CaPSURE) registry. Distribution primary use was measured time. cancer risk assessed using D'Amico groups Risk Assessment (CAPRA) score....
No AccessJournal of UrologyAdult Urology: Oncology: Prostate/Testis/Penis/Urethra1 Jun 2005THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CANCER THE PROSTATE RISK ASSESSMENT SCORE: A STRAIGHTFORWARD AND RELIABLE PREOPERATIVE PREDICTOR DISEASE RECURRENCE AFTER RADICAL PROSTATECTOMYis corrected byErrata MATTHEW R. COOPERBERG, DAVID J. PASTA, ERIC P. ELKIN, MARK S. LITWIN, M. LATINI, JANEEN Du CHANE, and PETER CARROLL COOPERBERGMATTHEW COOPERBERG More articles by this author , PASTADAVID PASTA...
This analysis uses data from the Cancer of Prostate Strategic Urologic Research Endeavor (CaPSURE) national registry to report on changes in types treatment patients with low-risk prostate cancer received 1990 through 2013.
Purpose Early intervention for prostate cancer is associated with excellent long-term survival, but many affected men, especially those low-risk disease characteristics, might not experience adverse impact to survival or quality of life were treatment deferred. We sought characterize temporal trends in clinical presentation and primary management among patients cancer. Methods Data abstracted from the Cancer Prostate Strategic Urologic Research Endeavor (CaPSURE), a registry 8,685 men...
Evidence exists to suggest a pattern of increasing early diagnosis renal cell carcinoma (RCC). The aim the study was analyze patterns disease presentation and outcome RCC by AJCC stage using data from National Cancer Data Base (NCDB) over 12-year period.The NCDB queried for adults diagnosed between 1993 2004 presenting with ICD-O-2 3 tumors arising in kidney. Cases were classified demographics, 2002 (6th edition), histology. Cochran-Armitage Test Trend used determine statistical significance...
We updated national risk trends in prostate cancer with a focus on low tumors, reexamined primary treatment for tumors and substratified patients at based pretreatment clinical data.Data were abstracted from the CaPSURE registry. A total of 10,385 men diagnosed between 1990 2006 localized disease. Low was defined as specific antigen 10 ng/ml or less, Gleason score 6 less T stage 2a less. Temporal assessed patient distribution among groups group individual factors, Kattan nomogram prediction,...
Abstract BACKGROUND: The authors previously developed and validated the Cancer of Prostate Risk Assessment (CAPRA) score to predict prostate cancer recurrence based on pretreatment clinical data. They aimed develop a similar postsurgical with improved accuracy via incorporation pathologic METHODS: A total 3837 prostatectomy patients in Strategic Urologic Research Endeavor (CaPSURE™) national disease registry were analyzed. Cox regression was used determine predictive power preoperative...
Abstract BACKGROUND. Active surveillance followed by selective treatment for men who have evidence of disease progression may be an option select patients with early‐stage prostate cancer. In this article, the authors report their experience in a contemporary cohort cancer were managed active surveillance. METHODS. All initially identified through authors' institutional database. Selection criteria included: prostate‐specific antigen (PSA) <10 ng/mL, biopsy Gleason sum ≤6 no pattern 4 or...
Purpose Older men are more likely to be diagnosed with high-risk prostate cancer and have lower overall survival. As a result, age often plays role in treatment choice. However, the relationships among age, disease risk, cancer–specific survival not been well established. Patients Methods We studied Cancer of Prostate Strategic Urologic Research Endeavor (CaPSURE) database complete treatment, follow-up information. High-risk patients were identified by using validated Risk Assessment (CAPRA)...
Black men are more likely to die of prostate cancer than white men. In with similar stages disease, the contribution biological vs nonbiological differences this observed disparity is unclear.To quantify association black race long-term survival outcomes after controlling for known prognostic variables and access care among cancer.This multiple-cohort study included updated individual patient-level data clinical T1-4N0-1M0 from following 3 cohorts: Surveillance, Epidemiology, End Results...
We aimed to validate a previously described genetic risk score, denoted the cell-cycle progression (CCP) in predicting contemporary radical prostatectomy (RP) outcomes.RNA was quantified from paraffin-embedded RP specimens. The CCP score calculated as average expression of 31 genes, normalized 15 housekeeper genes. Recurrence defined two prostate-specific antigen levels ≥ 0.2 ng/mL or any salvage treatment. Associations between and recurrence were examined, with adjustment for clinical...
Purpose To endorse Cancer Care Ontario’s guideline on Active Surveillance for the Management of Localized Prostate Cancer. The American Society Clinical Oncology (ASCO) has a policy and set procedures endorsing clinical practice guidelines developed by other professional organizations. Methods was reviewed developmental rigor methodologists. ASCO Endorsement Panel then content recommendations. Results determined that recommendations from guideline, published in May 2015, are clear, thorough,...
<h3>Importance</h3> Understanding the adverse effects of contemporary approaches to localized prostate cancer treatment could inform shared decision making. <h3>Objective</h3> To compare functional outcomes and associated with radical prostatectomy, external beam radiation therapy (EBRT), active surveillance. <h3>Design, Setting, Participants</h3> Prospective, population-based, cohort study involving 2550 men (≤80 years) diagnosed in 2011-2012 clinical stage cT1-2, cancer, prostate-specific...
Because no adequate randomized trials have compared active treatment modalities for localized prostate cancer, the authors analyzed risk-adjusted, cancer-specific mortality outcomes among men who underwent radical prostatectomy, received external-beam radiation therapy, and primary androgen-deprivation therapy.The Cancer of Prostate Strategic Urologic Research Endeavor (CaPSURE) registry comprises from 40 urologic practice sites are followed prospectively under uniform protocols, regardless...
Although many tools for the assessment of prostate cancer risk have been published, most are designed to predict only biochemical recurrence, usually after a single specified treatment. We assessed accuracy Cancer Prostate Risk Assessment (CAPRA) score, which was validated previously pathological and outcomes radical prostatectomy, metastases, cancer–specific mortality, all-cause mortality. studied 10 627 men with clinically localized in Strategic Urologic Research Endeavor registry, who...
<h3>Context</h3>Sexual function is the health-related quality of life (HRQOL) domain most commonly impaired after prostate cancer treatment; however, validated tools to enable personalized prediction erectile dysfunction treatment are lacking.<h3>Objective</h3>To predict long-term following based on individual patient and characteristics.<h3>Design</h3>Pretreatment characteristics, sexual HRQOL, details measured in a longitudinal academic multicenter cohort (Prostate Cancer Outcomes...
Active surveillance (AS) is an option for the initial management of early-stage prostate cancer. Current risk stratification schema identify patients with low-risk disease who are presumed to be most suitable AS. However, some men higher also elect AS; outcomes such have not been widely reported.Men managed AS at University California, San Francisco, were classified as low- or intermediate-risk based on serum prostate-specific antigen (PSA), Gleason grade, extent biopsy involvement, and T...
There is a clear need for molecular subtyping approach in prostate cancer to identify clinically distinct subgroups that benefit from specific therapies.To subtypes based on luminal and basal lineage determine associations with clinical outcomes response treatment.The PAM50 classifier was used subtype 1567 retrospectively collected (median follow-up, 10 years) 2215 prospectively samples into luminal- basal-like subtypes.Metastasis, biochemical recurrence, overall survival, cancer–specific...
The presence of pelvic nodal metastases at radical prostatectomy is associated with biochemical recurrence after prostatectomy.To assess the accuracy prostate-specific membrane antigen (PSMA) 68Ga-PSMA-11 positron emission tomographic (PET) imaging for detection compared histopathology time and lymph node dissection.This investigator-initiated prospective multicenter single-arm open-label phase 3 trial diagnostic efficacy enrolled 764 patients intermediate- to high-risk prostate cancer...